WITHDRAWN: The platelet membrane glycoprotein VI genetic polymorphism (rs1613662, 13254T>C) is not associated with the risk of coronary artery disease

Abstract

The platelet membrane glycoprotein VI (GP VI), encoded by GP6 gene, is the essential platelet collagen receptor and medicates platelet activation, adhesion and aggregation. Numerous studies revealed that the GP6 genetic polymorphisms may be associated with the susceptibility of coronary artery disease (CAD). However, a clear consensus has not yet been established. To investigate the association between GP6 genetic polymorphisms and CAD, the databases Pubmed, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang were searched for related studies. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to evaluate the strength of the association by using a random or fixed-effect model. Our analysis confirmed that there was no significant association between the GP6 13254T>C (Ser219Pro, rs1613662) genetic polymorphism and the risk of CAD under an allelic genetic model (OR = 1.00, 95% CI = 0.79-1.27; P = 0.988), a homozygous genetic model (OR = 1.14, 95% CI = 0.73-1.80; P = 0.563), a heterozygous genetic model (OR = 1.12, 95% CI = 0.95-1.33; P = 0.183), a recessive genetic model (OR = 1.11, 95% CI = 0.71-1.74; P = 0.652). Sensitivity and subgroup analysis indicated the robustness of the results. No publication bias existed between studies. In conclusion, no significant associations between GP6 13254T>C genetic polymorphism and CAD risk were found in this meta-analysis. More large-scale studies on the association of other GP6 genetic polymorphisms and the risk of CAD are needed to be performed in the future. www.impactjournals.com/oncotarget/ Vol.9, (No.1), Supplement 1, pp: s155-s165